​Oxford Vacmedix

We develop therapeutic agents for the treatment of cancer based on the invention of Professor Shisong Jiang – Recombinant Overlapping Peptides (ROP). Established in 2012 as a spinout from Oxford University. These agents are an exciting new way to deliver immunotherapy which is now a major focus in the treatment of cancer, making it easier to deliver, more effective and much more economical. The Company is also interested in collaborating with leading pharma companies that can provide checkpoint inhibitors suitable for combination with the novel ROP vaccines. Tony has previously held roles in the NHS and is a Trustee for a lung cancer charity. Professor Jiang is a globally renowned immunologist from Oxford University with previous experience at the Dana Farber Cancer Institute in the USA. Dr Thomas Morris is a physician who has worked in drug development for over 20 years, specialising in oncology. Mark has extensive experience leading global oncology clinical studies.